Trulicity

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
16-03-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
16-03-2023

Aktiivinen ainesosa:

dulaglutide

Saatavilla:

Eli Lilly Nederland B.V.

ATC-koodi:

A10BJ05

INN (Kansainvälinen yleisnimi):

dulaglutide

Terapeuttinen ryhmä:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Terapeuttinen alue:

Diabetes Mellitus, Type 2

Käyttöaiheet:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Tuoteyhteenveto:

Revision: 17

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2014-11-21

Pakkausseloste

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 16-03-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 16-03-2023
Pakkausseloste Pakkausseloste espanja 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 16-03-2023
Pakkausseloste Pakkausseloste tšekki 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 16-03-2023
Pakkausseloste Pakkausseloste tanska 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 16-03-2023
Pakkausseloste Pakkausseloste saksa 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 16-03-2023
Pakkausseloste Pakkausseloste viro 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto viro 16-03-2023
Pakkausseloste Pakkausseloste kreikka 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 16-03-2023
Pakkausseloste Pakkausseloste ranska 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 16-03-2023
Pakkausseloste Pakkausseloste italia 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto italia 16-03-2023
Pakkausseloste Pakkausseloste latvia 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 16-03-2023
Pakkausseloste Pakkausseloste liettua 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 16-03-2023
Pakkausseloste Pakkausseloste unkari 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 16-03-2023
Pakkausseloste Pakkausseloste malta 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto malta 16-03-2023
Pakkausseloste Pakkausseloste hollanti 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 16-03-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 16-03-2023
Pakkausseloste Pakkausseloste puola 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto puola 16-03-2023
Pakkausseloste Pakkausseloste portugali 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 16-03-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 16-03-2023
Pakkausseloste Pakkausseloste romania 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto romania 16-03-2023
Pakkausseloste Pakkausseloste slovakki 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 16-03-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 16-03-2023
Pakkausseloste Pakkausseloste sloveeni 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 16-03-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 16-03-2023
Pakkausseloste Pakkausseloste suomi 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 16-03-2023
Pakkausseloste Pakkausseloste ruotsi 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 16-03-2023
Pakkausseloste Pakkausseloste norja 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto norja 16-03-2023
Pakkausseloste Pakkausseloste islanti 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 16-03-2023
Pakkausseloste Pakkausseloste kroatia 16-03-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 16-03-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia